Drug Sales Trends for ADIPEX-P

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for ADIPEX-P

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ADIPEX-P			2022
ADIPEX-P			2021
ADIPEX-P			2020

Executive summary

Last updated: September 5, 2026

Adipex-P is a mature, low-cost brand of phentermine hydrochloride, a Schedule IV sympathomimetic approved for short-term obesity treatment. Its commercial market is driven by prescriptions for phentermine products, but generic substitution limits the brand’s pricing power and revenue potential. Adipex-P has no meaningful remaining innovator exclusivity, no durable patent moat, and faces competition from generic phentermine, phentermine/topiramate, GLP-1 therapies, and newer obesity drugs.

A reasonable U.S. base-case estimate is that the total phentermine market will remain broadly stable through 2028, with annual prescription volume near 9 million to 12 million prescriptions. Adipex-P brand sales are likely to remain a small portion of that market. Under modeled assumptions, U.S. Adipex-P net sales could range from approximately $10 million to $30 million annually, with downside risk if generic substitution increases or prescribers shift toward GLP-1 products.

Adipex-P Market Analysis, Patent Status, Competition, and Sales Projections

Adipex-P is a branded phentermine product with limited growth potential and high exposure to generic substitution. The product’s commercial value is linked to phentermine demand rather than proprietary intellectual property.

Metric	Assessment
Active ingredient	Phentermine hydrochloride
Dosage forms	37.5 mg tablets and capsules; lower-strength tablets also marketed
FDA status	Approved prescription drug
Therapeutic category	Sympathomimetic anorectic
Controlled-substance status	Schedule IV
Primary indication	Short-term adjunct to caloric restriction and exercise for obesity
Patent position	No meaningful remaining exclusivity identified
Market structure	Generic-dominated
Main U.S. competitors	Generic phentermine, Lomaira, Qsymia, Wegovy, Zepbound, Saxenda
Main commercial risk	Generic substitution and migration to newer anti-obesity medicines

What is Adipex-P and how is it used?

Adipex-P contains phentermine hydrochloride, a sympathomimetic amine with pharmacologic activity similar to the prototype anorectic agents. The FDA-approved labeling limits use to short-term treatment, generally interpreted as a few weeks, in patients with an initial body mass index of at least 30 kg/m² or at least 27 kg/m² with risk factors such as hypertension, diabetes, or hyperlipidemia.[1]

The most commonly prescribed strength is 37.5 mg. Physicians also use lower-dose phentermine products, particularly when attempting to reduce adverse effects or tailor dosing.

Adipex-P is not approved as a chronic obesity therapy in the same manner as semaglutide or tirzepatide. Its low cost, broad clinician familiarity, oral administration, and availability through cash-pay channels support continued use despite its older label and narrower indication.

How large is the U.S. phentermine market?

Phentermine remains one of the largest prescription obesity-drug markets by prescription volume, although its revenue per prescription is low.

Public prescription datasets have historically placed phentermine among the most frequently dispensed anti-obesity drugs in the United States. Depending on the reporting source, market year, and whether all generic strengths and branded products are included, annual U.S. volume is reasonably modeled at approximately 9 million to 12 million prescriptions.[2]

The market has two distinct segments:

1. A high-volume, low-price generic segment.
2. A smaller branded and cash-pay segment, including Adipex-P and Lomaira.

The market’s prescription volume does not translate directly into manufacturer revenue. Generic phentermine is widely available at low prices, and many patients pay cash because obesity medicines often have limited commercial insurance coverage. Retail cash prices can vary substantially by pharmacy, strength, quantity, and discount program.

Estimated U.S. phentermine market structure

Segment	Estimated share of prescriptions	Commercial characteristics
Generic phentermine	90% to 97%	Low price, broad availability, high substitution
Adipex-P	1% to 5%	Brand recognition, limited pricing power
Lomaira and other branded presentations	1% to 4%	Low-dose positioning and niche prescribing
Other phentermine-containing products	Less than 1%	Limited commercial contribution

These percentages are analytical estimates rather than reported manufacturer market shares. Adipex-P sales are not publicly disclosed as a standalone product line.

What patents protect Adipex-P?

Adipex-P does not appear to have an active patent estate capable of protecting its core commercial market.

Phentermine hydrochloride has been marketed for decades. Any foundational composition, formulation, or use patents associated with the original product have expired. The active ingredient is available from multiple generic manufacturers, and FDA-approved generic products compete directly with Adipex-P.

The key commercial protections are therefore non-patent factors:

• Brand recognition.
• Physician familiarity.
• Availability in common dosage strengths.
• Pharmacy distribution.
• Manufacturer supply reliability.
• Patient preference for a branded product.
• Cash-pay marketing and prescribing channels.

Orange Book status and regulatory exclusivity

Protection category	Adipex-P assessment
Active ingredient patent	No meaningful active protection identified
Formulation patent	No material current protection identified
Method-of-use patent	No material current protection identified
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current protection identified
Regulatory exclusivity	No current exclusivity identified
Orange Book commercial effect	Generic competition remains permitted

FDA Orange Book protection is most relevant when listed patents block or delay abbreviated new drug applications. Adipex-P’s market position does not depend on an active Orange Book patent barrier.[3]

When does Adipex-P lose exclusivity?

Adipex-P has already lost meaningful market exclusivity.

The product’s competitive position is consistent with a mature off-patent medicine. Generic phentermine products are approved under the abbreviated new drug application pathway and can compete based on bioequivalence rather than repeating the full clinical development program required for a new chemical entity.

There is no credible basis for projecting a future patent cliff for Adipex-P because the principal loss of exclusivity occurred many years ago. The relevant business issue is not when exclusivity ends, but how quickly generic substitution and newer obesity therapies reduce branded demand.

Which companies compete with Adipex-P?

Generic phentermine manufacturers

Generic phentermine is manufactured or distributed by numerous U.S. companies. The market includes manufacturers such as Hikma Pharmaceuticals, Amneal Pharmaceuticals, Elite Pharmaceuticals, KVK-Tech, Lannett, Zydus, and other FDA-approved suppliers, subject to product availability and changes in ownership or distribution arrangements.

Generic competition is the primary threat because products are therapeutically substitutable and usually priced below the brand.

Branded phentermine products

Lomaira is a lower-dose phentermine product marketed for obesity treatment. It competes through dose flexibility and positioning rather than a fundamentally different mechanism.

Phentermine/topiramate

Qsymia combines phentermine with extended-release topiramate. It is approved for chronic weight management and has a broader label than Adipex-P. Qsymia has faced generic and patent-related competitive pressure, but its combination formulation and chronic-use positioning distinguish it from immediate-release phentermine.

GLP-1 and dual incretin therapies

The largest strategic threat comes from chronic therapies with greater average weight loss and broader commercial attention:

Product	Active ingredient	Manufacturer	Relevance to Adipex-P
Wegovy	Semaglutide	Novo Nordisk	High efficacy, injectable, chronic treatment
Zepbound	Tirzepatide	Eli Lilly	High efficacy, injectable, chronic treatment
Saxenda	Liraglutide	Novo Nordisk	Established GLP-1 obesity product
Contrave	Naltrexone/bupropion	Currax	Oral alternative with chronic-use labeling
Qsymia	Phentermine/topiramate	Vivus, now associated with Corium commercialization	Direct pharmacologic adjacency

Wegovy and Zepbound have higher acquisition costs, more complex access requirements, and injection-related barriers. Adipex-P retains a cost advantage, especially for uninsured patients and patients seeking short-term pharmacologic assistance.

What is the FDA regulatory status of Adipex-P?

Adipex-P is FDA-approved as a short-term adjunct to lifestyle intervention for exogenous obesity.[1] Its labeling includes contraindications for patients with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, or a history of drug abuse, among other restrictions.

Phentermine is a Schedule IV controlled substance under the federal Controlled Substances Act. State prescribing rules may impose additional requirements, including limits on duration, refill procedures, telehealth prescribing, and monitoring.

The regulatory profile creates both support and constraint:

• The long clinical history supports physician familiarity.
• The controlled-substance classification restricts distribution and prescribing.
• The short-term label limits direct positioning against chronic obesity therapies.
• Safety concerns can reduce use in patients with cardiovascular or psychiatric risk.
• No new FDA exclusivity is available for the existing product.

What are the main formulation and manufacturing barriers?

Adipex-P has low manufacturing complexity compared with injectable biologics and modified-release obesity products. Phentermine hydrochloride is a small-molecule active ingredient that can be formulated into conventional tablets and capsules.

Manufacturing barriers are therefore operational rather than technological:

• Controlled-substance handling and recordkeeping.
• Active pharmaceutical ingredient supply.
• FDA quality-system compliance.
• Consistent tablet dissolution and content uniformity.
• Packaging and distribution controls.
• Product availability during generic supply disruptions.

There is no comparable manufacturing barrier to the aseptic production, device assembly, and cold-chain distribution required for GLP-1 injectables. That cost advantage supports continued supply of low-priced phentermine, but it also makes entry by additional generic manufacturers easier.

What patent litigation or Paragraph IV risk affects Adipex-P?

Adipex-P has limited current Paragraph IV litigation exposure because its core product is already off patent.

Paragraph IV litigation generally arises when a generic applicant challenges an unexpired Orange Book patent. Since Adipex-P’s principal market protections have expired, future litigation is more likely to involve:

• A newer phentermine formulation.
• A combination product.
• A delivery system.
• A manufacturing process.
• A competing branded product with separate patent claims.

Generic phentermine applicants do not need to overcome a meaningful Adipex-P patent barrier. There is no central, commercially important patent settlement controlling generic entry into the basic phentermine market.

How strong is the Adipex-P patent estate?

Patent-estate factor	Rating	Analysis
Core compound protection	Very weak	Historical patents expired
Formulation protection	Very weak	Conventional dosage forms are widely available
Method-of-use protection	Weak	Existing label is mature and generic competition is established
Manufacturing protection	Weak	Multiple suppliers can manufacture the product
Regulatory exclusivity	None identified	No current exclusivity barrier
Brand protection	Moderate	Trademark and recognition provide limited differentiation
Overall patent strength	Very weak	Commercial value depends on brand and distribution

Adipex-P may retain trademark value, but trademark protection does not prevent approval or sale of generic phentermine. It can prevent confusingly similar branding, not therapeutic substitution.

What are Adipex-P sales projections through 2028?

Because Adipex-P sales are not separately reported, projections require a market-share and net-price model. The following base case assumes:

• U.S. phentermine prescriptions remain near 10 million annually.
• Adipex-P captures 2% to 3% of branded and generic-equivalent prescription volume.
• Realized manufacturer net sales per prescription remain approximately $5 to $12 after discounts, rebates, wholesaler deductions, and channel effects.
• GLP-1 migration gradually reduces total phentermine volume.
• No material supply interruption occurs.

U.S. Adipex-P sales projection

Year	Total phentermine prescriptions	Estimated Adipex-P share	Estimated Adipex-P prescriptions	Estimated net sales
2024	9.5M to 11.5M	2.0% to 3.0%	190K to 345K	$1M to $4M
2025	9.3M to 11.3M	2.0% to 3.0%	186K to 339K	$1M to $4M
2026	9.0M to 11.0M	1.8% to 2.8%	162K to 308K	$1M to $4M
2027	8.7M to 10.8M	1.7% to 2.7%	148K to 292K	$1M to $4M
2028	8.4M to 10.5M	1.5% to 2.5%	126K to 263K	$1M to $3M

These figures represent estimated manufacturer net sales, not retail sales. If Adipex-P is sold through a higher-priced cash-pay channel or has a materially higher brand share than modeled, annual sales could exceed the base range.

Scenario analysis

Scenario	2028 phentermine volume	Adipex-P share	2028 estimated net sales	Primary driver
Downside	7.5M to 9.0M	1.0% to 1.5%	$0.5M to $2M	Rapid GLP-1 migration and generic substitution
Base case	8.4M to 10.5M	1.5% to 2.5%	$1M to $3M	Stable low-cost use with gradual erosion
Upside	10.5M to 12.0M	3.0% to 4.0%	$4M to $10M	Cash-pay brand preference and GLP-1 access barriers

A higher retail sales estimate is possible if sales are measured at pharmacy checkout rather than manufacturer net revenue. The difference can be substantial because cash prices, discount cards, wholesaler margins, and pharmacy margins are not equivalent to branded product revenue.

What generic entry risks exist for Adipex-P?

The generic-entry risk is effectively realized rather than prospective. Generic phentermine is already established. Future downside is more likely to come from share erosion than a discrete launch event.

Key risks include:

• Pharmacies automatically substituting generic phentermine.
• Manufacturers reducing Adipex-P promotional support.
• Patients choosing lower-cost generic products.
• Telehealth providers prescribing generic phentermine.
• Payers excluding branded phentermine.
• Broader adoption of semaglutide and tirzepatide.
• Increased scrutiny of long-term or repeated phentermine use.
• Supply disruptions that shift patients toward competing products.

Adipex-P’s main defense is price relative to newer therapies, but generic phentermine has the same price advantage without the brand premium.

How does Adipex-P compare with Wegovy, Zepbound, and Qsymia?

Attribute	Adipex-P	Qsymia	Wegovy	Zepbound
Route	Oral	Oral	Injection	Injection
Typical use	Short term	Chronic	Chronic	Chronic
Active ingredient class	Sympathomimetic	Combination	GLP-1 agonist	GIP/GLP-1 agonist
Relative cost	Low	Moderate to high	High	High
Weight-loss efficacy	Lower	Moderate	High	High
Generic competition	Extensive	Emerging or developing	No conventional generic equivalent currently	No conventional generic equivalent currently
Main access advantage	Cash affordability	Chronic oral option	Strong clinical efficacy	Strong clinical efficacy
Main commercial weakness	Short-term label and safety limits	Cost and tolerability	Cost and access	Cost and access

Adipex-P is most competitive where patients lack insurance coverage, cannot obtain GLP-1 medicines, or prefer an oral low-cost option. It is less competitive in chronic obesity-management programs that prioritize durable weight reduction and long-term treatment.

What licensing deals affect Adipex-P?

No major recent licensing transaction appears to define Adipex-P’s current commercial outlook. The product is a mature branded medicine rather than a platform asset with meaningful partnering value.

Potential transaction value would likely relate to:

• A portfolio acquisition involving multiple generic and branded products.
• Distribution rights in a specific market.
• A controlled-substance commercial platform.
• Manufacturing or supply arrangements.
• A broader obesity-treatment portfolio.

A standalone Adipex-P licensing deal would likely have limited strategic value unless the buyer controls a differentiated distribution channel or combines the product with digital weight-management services.

Key Takeaways

• Adipex-P is a mature branded phentermine product with no meaningful remaining patent moat.
• Generic phentermine controls most prescription volume and limits brand pricing power.
• The total U.S. phentermine market can reasonably remain near 9 million to 12 million prescriptions annually in the near term, with gradual erosion from GLP-1 therapies.
• Estimated Adipex-P manufacturer net sales are likely in the low-single-digit millions annually under a base-case model.
• The product’s main commercial advantages are low cost, oral dosing, physician familiarity, and availability.
• Its main risks are generic substitution, the short-term FDA label, controlled-substance restrictions, and migration to Wegovy and Zepbound.
• Paragraph IV litigation and patent-settlement risk are limited because the core product is already off patent.
• The principal investment question is distribution economics, not intellectual property protection.

FAQs

Is Adipex-P still under patent protection?

No meaningful active patent protection is expected to prevent generic phentermine competition. The product’s core compound and conventional dosage-form protections expired long ago.

Is Adipex-P included in the FDA Orange Book?

Adipex-P is an FDA-approved prescription product, but its commercial position does not depend on an active Orange Book patent listing that blocks generic phentermine.

Can generic phentermine replace Adipex-P?

Yes. FDA-approved generic phentermine products are intended to be therapeutically equivalent to the corresponding branded dosage forms, subject to product-specific strength, formulation, and substitution rules.

Will Wegovy and Zepbound eliminate the Adipex-P market?

No. They are likely to reduce long-term growth and take share from some patients, but Adipex-P retains a cost and access advantage for uninsured or cash-pay patients.

What is the most likely Adipex-P revenue trend through 2028?

The most likely trend is flat to declining revenue, with a base-case U.S. manufacturer net-sales range of approximately $1 million to $3 million annually by 2028. Retail sales may be higher depending on channel margins and cash-pay pricing.

References

1. U.S. Food and Drug Administration. (n.d.). Adipex-P (phentermine hydrochloride) prescribing information. FDA.
2. ClinCalc. (n.d.). The top 200 drugs of 2023. ClinCalc DrugStats.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. U.S. Department of Justice.
5. U.S. Food and Drug Administration. (n.d.). Wegovy (semaglutide) prescribing information. FDA.
6. U.S. Food and Drug Administration. (n.d.). Zepbound (tirzepatide) prescribing information. FDA.